Korro Bio, Inc. (KRRO) stock
Close on Nov 11, 2026Market cap $212.20MP/E –Yield –
Korro Bio, Inc. saw revenue fall 82.5% to $1.29M over the twelve months to Sep 30, 2026. Free cash flow was -$63.87M. At the latest close the market valued the company at $212.20M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $212.20M
- P/E ratio
- –
- Price to sales
- 164.24
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -30.10%
Fundamentals
- Revenue
- $1.29M
- Net income
- -$106.13M
- EPS, diluted
- -$9.06
- Free cash flow
- -$63.87M
- Diluted shares
- 18M
Trading
- Next earnings
- Mar 11, 2027 (estimated, after the close)
- Previous close
- $15.73
- Open
- $15.70
- Day's range
- $14.10 – $15.70
- Volume
- 192,694
- Average volume (20 days)
- 242,328
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 2.11
- 52-week range
- $5.20 – $33.91
- RSI (14 days)
- 57.7
- Volatility (1 year)
- 118.6%
- Relative volume
- 1.12×
- WACC
- 15.4%
On 1 of our idea list: Insiders buying the dip
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | KRRO | S&P 500 | Difference | KRRO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +41.8% | -2.4% | +44.2 pts | ||
| 3 months | +8.2% | -1.2% | +9.3 pts | ||
| Year to date | +79.9% | +12.3% | +67.6 pts | ||
| 1 year | -56.1% | +12.4% | −68.5 pts | ||
| 3 years | -66.1% | +78.8% | −144.9 pts | -30.3% | +21.4% |
| 5 years | -95.5% | +75.2% | −170.7 pts | -46.3% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Korro Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Results
- News
- News
About Korro Bio
Pharmaceutical Preparations
Korro Bio, Inc. is a biopharmaceutical company that discovers, develops, and commercializes genetic medicines utilizing RNA editing technology to treat rare and highly prevalent human illnesses. The company employs its proprietary OPERA platform alongside oligonucleotides to harness the natural adenosine deaminase acting on RNA enzyme, creating transient single-nucleoside edits rather than permanent alterations to DNA. Its wholly-owned preclinical development pipeline includes KRRO-121 for hyperammonemia, an oligonucleotide program for alpha-1 antitrypsin deficiency, an AMPK gamma 1 activation program for liver health, and a therapy targeting TDP-43 for amyotrophic lateral sclerosis. The company designs its therapies for patient populations affected by metabolic, genetic, and neurodegenerative disorders.
Company profile, executives and historyKorro Bio stock: common questions
What is Korro Bio's stock price?
KRRO closed at $14.41 on Nov 11, 2026, down 8.39% on the day. Over the past 52 weeks it traded between $5.20 and $33.91.
What is Korro Bio's market cap?
Korro Bio was worth $212.20M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is KRRO's P/E ratio?
Korro Bio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$9.06), so it has no meaningful P/E ratio.
How much revenue does Korro Bio make?
Korro Bio reported revenue of $1.29M for the twelve months to Sep 30, 2026, down 82.5% from a year earlier.
Does Korro Bio pay a dividend?
No. Korro Bio has not paid a cash dividend over the last twelve months.
When does Korro Bio report earnings next?
Korro Bio is expected to report Q4 FY2026 results on Mar 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has KRRO stock performed over the past year?
Including dividends, KRRO returned -56.1% over the past year, against +12.4% for the S&P 500.
How many KRRO shares are sold short?
2M shares were sold short at the latest FINRA report, 16.39% of the float, or 8.2 days of average trading volume.
Who are Korro Bio's competitors?
Companies most similar to Korro Bio by business, industry and size include TRDA, CAMP, MCRB, NGNE, OVID.
See a number that looks wrong?